Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2024 | The ANCHOR and LIGHTHOUSE trials: melfulfen combination treatment in RRMM

Enrique Ocio • 25 May 2024
COMy 2024
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Melflufen
ANCHOR LIGHTHOUSE

Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the ANCHOR trial (NCT03481556), which investigated melphalan flufenamide (melflufen) with dexamethasone plus either bortezomib or daratumumab in relapsed/refractory multiple myeloma (RRMM). The trial showed good responses and tolerability in both arms. These positive results led to the Phase III LIGHTHOUSE study (NCT04649060), which found a significant benefit of combining melflufen, dexamethasone, and daratumumab compared to daratumumab alone. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Honoraria/Consultancy: Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD, Mundipharma-EDO.

More from Enrique Ocio

The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma 1:28
The possibility of integrating CELMoDs, CAR T-cells & bispecifics into first-line therapy in myeloma
Enrique Ocio • 8 Dec 2024
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts 1:08
Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
Enrique Ocio • 8 Dec 2024
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma 1:16
A pilot study investigating a shorter duration of isatuximab infusion in patients with myeloma
Enrique Ocio • 8 Dec 2024
Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myeloma 1:53
Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myeloma
Enrique Ocio • 8 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals